Analyst action: LP, Noranda

Two of Middle Tennessee's publicly traded manufacturers have been on the sharp end of some analyst moves in recent days. At RBC Capital Markets, Stephen Atkinson lowered his rating on Louisiana-Pacific (Ticker: LPX) to 'sector perform' from 'outperform' but kept his $8 price target. Scotia Capital's Benoit Laprade has made a similar move — from 'sector perform' to 'underperform' — but actually raised his target slightly to $8.25.

Over at Bank of America Merrill Lynch, Oscar Cabrera has lowered his price target for shares of Noranda Aluminum to $8 from $10, 50 cents below where the stock (Ticker: NOR) is changing hands this morning. The culprit: A lower forecast for 2012 aluminum prices.

Dec 6, 2011 9:38 AM

Analyst action: LP, HCA

Benoit Laprade at Scotia Capital has upgraded shares of building products manufacturer Louisiana-Pacific to 'sector perform' from 'underperform.' Shares of Nashville-based LP (Ticker: LPX) are down about 6 percent year to date.

Wells Fargo analyst Gary Lieberman is the latest to come out with a recommendation on shares of the newly public HCA. He has launched coverage of the hospital giant with an 'outperform' rating and price target range of $34 to $39. HCA (Ticker: HCA) closed Monday trading at $32.08.

Apr 19, 2011 7:39 AM

Analyst action: LP, Healthways

Scotia Capital analyst Benoit Laprade has for the third time this year changed his rating on the shares of Louisiana-Pacific. He now rates them at 'sector underperform,' down two notches from his previous rating. LP shares (Ticker: LPX) have risen more than 30 percent this year. Looking for a 2011 best idea in the health care space? Well, look no further than Healthways, say the researchers at FBR Capital. Its role in the health care services/pharmacy sector will help drive results as insurance reform and economic recovery take hold. There is, of course, also a value-play element to picking Healthways: Its shares (Ticker: HWAY) are down more than 40 percent in 2010.
Dec 16, 2010 12:57 PM

Analyst action: LP, BioMimetic

Two local stocks have had their price targets lowered today by analysts. Benoit Laprade at Scotia Capital has raised his rating on construction materials supplier Louisiana-Pacific to 'sector outperform' but has dinked his target down to $10.25 from $11. Shares of downtown-based LP (Ticker: LPX) are up more than 5 percent to about $7 today and have crept back into positive territory for the year. Shares of BioMimetic Therapeutics also are outpacing the broader market today despite a lowered target by Canaccord Genuity analyst William Plovanic. Plovanic reiterated his 'buy' recommendation, however, which has helped the stock (Ticker: BMTI) push 1.5 percent higher.

Jun 30, 2010 1:54 PM

Analyst action: LP, NHI

Shares of National Health Investors have been downgraded to 'hold' from 'buy' by Stifel Nicolaus analyst Jerry Doctrow, who's making a habit of yo-yoing his recommendations. The Murfreesboro-based REIT (Ticker: NHI) has risen about 5 percent in the past six months but is off about 1 percent this morning. At Scotia Capital, Benoit Laprade has downgraded Louisiana-Pacific to 'underperform' from 'perform' but maintained his $8 price target. Shares of Nashville-based LP (Ticker: LPX) are down 7 percent this morning but have risen about 17 percent in the past six months.
Feb 23, 2010 10:56 AM